4D pharma plc Appoints two independent Non-Executive Directors

4d pharma plc
[shareaholic app="share_buttons" id_name="post_below_content"]

4D pharma plc (LON: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announced the appointment of Ed Baracchini, PhD, and Professor Axel Glasmacher, MD, as independent Non-Executive Directors with immediate effect.

Ed Baracchini, PhD, was previously the Chief Business Officer at Xencor Inc. where he led strategic alliances and licensing. During his time at Xencor he negotiated license agreements with Novartis ($2.6B: immune-oncology bispecific antibodies), Novo Nordisk ($600M: drug discovery collaboration), Amgen ($500M: option and development agreement autoimmune disease antibody) among numerous others. Prior to that he served as SVP Business Development for Metabasis Therapeutics.

Professor Dr. med. Axel Glasmacher was until recently Senior Vice President and Head of the Global Clinical Research and Development Hematology-Oncology at Celgene, where he has worked in various roles for more than ten years. His work at Celgene led to the approvals of Revlimid®, Idhifa®, and Vidaza® (haematological cancers). He also worked on the PD-L1 inhibitor durvalumab. Prior to Celgene, Professor Glasmacher worked within the fields of hematology-oncology at the University Hospital in Bonn.

Duncan Peyton, 4D’s Chief Executive Officer, commented:

“We welcome Axel and Ed to our Board with great pleasure. Their collective experience will strengthen our commercial and therapeutic focus, as 4D accelerates development of its extensive pipeline in cancer and other immunological diseases.”

The following information is disclosed in accordance with Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for Companies.

Edgardo (Ed) Baracchini Jr., 59, has no interest in shares in 4D pharma plc and has the following current and previous company directorships and partnerships:

Current Company Directorships and Partnerships:

None

Company Directorships and Partnerships held in last 5 years:

INmune Bio, Inc.

Axel Gaston Glasmacher, 58, has no interest in shares in 4D pharma plc and has the following current and previous company directorships and partnerships:

Current Company Directorships and Partnerships:

AG Life Science Consulting GmbH & Co. KG – finalisation of formal incorporation pending

Glasmacher Verwaltungs-GmbH – finalisation of formal incorporation pending

Company Directorships and Partnerships held in last 5 years:

None

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search